Novo Nordisk Announces $6 Billion Investment to Expand Danish Manufacturing Facilities

"Weight-loss Wonder Drug" Manufacturer Novo Nordisk announced on Friday that it will invest over 42 billion Danish kroner (approximately 6 billion US dollars) starting from 2023 to expand its production facilities in Denmark, for the production of current and future portfolios of severe chronic disease products. The company stated that part of this investment has already been included in the 25 billion kroner capital expenditure announced in February. (Sina Finance)Original link